Geode Capital Management
CLDX icon

Geode Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Geode Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.3M Buy
2,022,226
+334,152
+20% +$10.8M ﹤0.01% 1400
2026
Q1 		$53.6M Buy
1,688,074
+60,545
+4% +$1.65M ﹤0.01% 1457
2025
Q4 		$44.2M Sell
1,627,529
-19,607
-1% -$516K ﹤0.01% 1562
2025
Q3 		$42.6M Sell
1,647,136
-25,844
-2% -$599K ﹤0.01% 1575
2025
Q2 		$34M Buy
1,672,980
+83,174
+5% +$1.62M ﹤0.01% 1642
2025
Q1 		$28.9M Buy
1,589,806
+54,890
+4% +$1.23M ﹤0.01% 1694
2024
Q4 		$38.8M Sell
1,534,916
-5,597
-0.4% -$152K ﹤0.01% 1594
2024
Q3 		$52.4M Buy
1,540,513
+6,557
+0.4% +$250K ﹤0.01% 1397
2024
Q2 		$56.8M Buy
1,533,956
+119,578
+8% +$4.51M 0.01% 1271
2024
Q1 		$59.4M Buy
1,414,378
+296,384
+27% +$12.2M 0.01% 1238
2023
Q4 		$44.3M Buy
1,117,994
+117,569
+12% +$3.46M ﹤0.01% 1419
2023
Q3 		$27.5M Buy
1,000,425
+35,352
+4% +$1.11M ﹤0.01% 1622
2023
Q2 		$32.7M Buy
965,073
+39,365
+4% +$1.33M ﹤0.01% 1526
2023
Q1 		$33.3M Buy
925,708
+42,173
+5% +$1.82M ﹤0.01% 1465
2022
Q4 		$39.4M Buy
883,535
+30,829
+4% +$1.1M 0.01% 1322
2022
Q3 		$24M Buy
852,706
+11,582
+1% +$355K ﹤0.01% 1601
2022
Q2 		$22.7M Sell
841,124
-14,389
-2% -$418K ﹤0.01% 1675
2022
Q1 		$29.1M Buy
855,513
+45,093
+6% +$1.44M ﹤0.01% 1630
2021
Q4 		$31.3M Buy
810,420
+17,913
+2% +$781K ﹤0.01% 1663
2021
Q3 		$42.8M Buy
792,507
+119,559
+18% +$5.61M 0.01% 1408
2021
Q2 		$22.5M Buy
672,948
+320,251
+91% +$8.79M ﹤0.01% 1888
2021
Q1 		$7.26M Buy
352,697
+53,643
+18% +$1.23M ﹤0.01% 2580
2020
Q4 		$5.24M Buy
299,054
+41,425
+16% +$746K ﹤0.01% 2579
2020
Q3 		$3.82M Buy
257,629
+127,392
+98% +$1.49M ﹤0.01% 2554
2020
Q2 		$1.69M Buy
130,237
+26,254
+25% +$116K ﹤0.01% 2928
2020
Q1 		$172K Hold
103,983
– – ﹤0.01% 3593
2019
Q4 		$231K Buy
103,983
+790
+0.8% +$1.83K ﹤0.01% 3749
2019
Q3 		$219K Hold
103,193
– – ﹤0.01% 3733
2019
Q2 		$276K Sell
103,193
-5,112
-5% -$17.4K ﹤0.01% 3689
2019
Q1 		$532K Buy
108,305
+33,644
+45% +$177K ﹤0.01% 3418
2018
Q4 		$221K Buy
74,661
+6,186
+9% +$30.4K ﹤0.01% 3644
2018
Q3 		$463K Sell
68,475
-444
-0.6% -$3.11K ﹤0.01% 3489
2018
Q2 		$520K Sell
68,919
-6,058
-8% -$81K ﹤0.01% 3426
2018
Q1 		$2.62M Buy
74,977
+1,261
+2% +$48.9K ﹤0.01% 2620
2017
Q4 		$3.14M Buy
73,716
+9,872
+15% +$423K ﹤0.01% 2496
2017
Q3 		$2.74M Buy
63,844
+1,056
+2% +$39.6K ﹤0.01% 2567
2017
Q2 		$2.33M Buy
62,788
+3,869
+7% +$171K ﹤0.01% 2646
2017
Q1 		$3.19M Buy
58,919
+6,541
+12% +$341K ﹤0.01% 2387
2016
Q4 		$2.78M Buy
52,378
+1,540
+3% +$87.6K ﹤0.01% 2442
2016
Q3 		$3.08M Buy
50,838
+5,893
+13% +$367K ﹤0.01% 2282
2016
Q2 		$2.96M Buy
44,945
+306
+0.7% +$19.4K ﹤0.01% 2221
2016
Q1 		$2.53K Buy
44,639
+732
+2% +$82.4K ﹤0.01% 2295
2015
Q4 		$10.3M Buy
43,907
+1,493
+4% +$325K 0.01% 1360
2015
Q3 		$6.71M Sell
42,414
-240
-0.6% -$67.9K ﹤0.01% 1637
2015
Q2 		$16.1M Buy
42,654
+2,141
+5% +$850K 0.01% 1074
2015
Q1 		$16.9M Buy
40,513
+5,690
+16% +$2.04M 0.01% 1020
2014
Q4 		$9.53M Buy
34,823
+905
+3% +$225K 0.01% 1373
2014
Q3 		$6.59M Buy
33,918
+40
+0.1% +$8.71K ﹤0.01% 1582
2014
Q2 		$8.29M Buy
33,878
+158
+0.5% +$35.7K 0.01% 1446
2014
Q1 		$8.94M Buy
33,720
+3,232
+11% +$1.24M 0.01% 1334
2013
Q4 		$11.1M Buy
30,488
+2,705
+10% +$1.04M 0.01% 1116
2013
Q3 		$14.8M Buy
27,783
+5,285
+23% +$1.81M 0.01% 839
2013
Q2 		$5.27M Buy
+22,498
New +$4.43M ﹤0.01% 1385

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Geode Capital Management's CLDX Position: Q2 2026 in Review

Geode Capital Management increased its Celldex Therapeutics (CLDX) stake by 20% in Q2 2026, buying an estimated $10.8M and bringing the position to 2,022,226 shares worth $75.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1400.

Geode Capital Management first reported a position in CLDX in Q2 2013 and has held it in 53 quarters since. 234 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Geode Capital Management held 2,022,226 shares of Celldex Therapeutics worth $75.3M as of Q2 2026.
  • Geode Capital Management bought 334,152 Celldex Therapeutics shares in Q2 2026, an estimated $10.8M.
  • Celldex Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1400 holding.
  • Geode Capital Management first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 234 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.